Johnson & Johnson (JNJ): Buying Isn’t for Growth Investors

If there’s one health-care stock every investor knows by name, it’s Johnson & Johnson (NYSE:JNJ). This industry titan makes everything from consumer health products to medical devices to pharmaceuticals, reaching into every niche of the medical sector. It’s a strong dividend stock with a history of stability — there’s seemingly some perk for every  J&J investor.

Johnson & Johnson (JNJ)However, growth investors might want to take a look elsewhere. For all J&J does right, it’s anything but a fast-growing, chart-topping stock for those looking for the best possible annual returns. While J&J isn’t short on financial growth and makes a great foundation for any portfolio, a few key trends should make growth investors think twice before doubling up on shares.

Core businesses, slow growth
J&J is much more than a medicine company, and is far more diverse than its Big Pharma rivals. It is heavily reliant on sales of consumer health products and medical devices. In 2012, these two segments made up more than 62% of all revenue.

Unfortunately for growth investors, these two segments aren’t exactly setting the markets on fire. Consumer health sales are a great, stable foundation for risk-averse investors, but there’s little growth to be had here: Revenue fell at five of the six consumer health businesses last year, with only oral-care sales remaining flat. With tightening consumer wallets and hospital budgets under pressure, expect that trend to keep up in the near future.

Medical devices can be a great growth driver: J&J proved as much when the company bought orthopedics firm Synthes last year in a $12 billion deal. That acquisition sparked a huge jump in the company’s orthopedics revenue. Unfortunately, J&J’s most recent earnings report has shown that without the Synthes deal, revenue growth has been elusive for the company’s medical device segments.

Orthopedics revenue should continue to grow in the future: Rival Stryker Corporation (NYSE:SYK) recently posted growing orthopedics revenue despite its troubles with hip implant recalls and pricing pressures in the industry, and age and obesity-related trends should keep demand high for years to come. J&J’s other medical device segments haven’t been so lucky recently, and slow, steady growth outside of orthopedics looks to stick around for some time as the medical device industry struggles.

If medical device revenue and consumer health sales aren’t growing at a good clip, pharmaceuticals can always drive growth. Unfortunately, while J&J’s drug business is top-notch, it’s not lighting up the markets like a fresh, new biotech firm.

Diluting the blockbuster drugs
J&J’s pharmaceutical business is massive, covering everything from oncology to immunology and more. That treatment diversity is a blessing for income investors and shareholders seeking stability in a volatile industry like health care, but for growth investors, it can be a curse.

The company reported strong growth in several promising drugs last year, including more than 300% year-over-year sales growth from likely future blockbuster prostate cancer treatment Zytiga. This wasn’t enough to ward off falling sales from patent expirations. Growth slipped from 8.8% in 2011 to just 4% last year, and while the future’s bright for J&J’s pharmaceutical business with potential future blockbusters such as diabetes-fighting Invokana, this segment’s diversity of drugs and therapies dilute the effect of up-and-coming drug candidates on overall growth.

This is a problem that affects Big Pharma companies across the sector, but major firms in pharmaceuticals and biotech have managed to grow significantly while concentrating on smaller, more focused drug portfolios. Consider Biogen Idec Inc. (NASDAQ:BIIB): The firm’s considerable focus on multiple sclerosis drugs exposes it to far more risk than Johnson & Johnson (NYSE:JNJ)’s well-diversified portfolio, but it’s still a far safer pick than up-and-coming biotech firms with murky futures. That hasn’t stopped Biogen Idec Inc. (NASDAQ:BIIB) shares from soaring more than 59% over the past year, nearly double J&J’s performance.

The problem with diversity
All of this adds up to the most important reason why J&J isn’t the best bet for growth investors: This company is simply too broad and diversified to realize chart-topping growth for any long period of time.

Other leading firms in the health-care field have caught on. Pfizer Inc. (NYSE:PFE) has made some of the strongest moves to concentrate on its core recently, selling its infant nutrition business to Nestle and spinning off its former animal health business, Zoetis Inc (NYSE:ZTS), in order to unlock shareholder value. These moves not only allowed Pfizer Inc. (NYSE:PFE) to concentrate on its high-growth, boom-or-bust pharmaceutical business, but also, as a secondary effect, made the stock attractive to growth investors by focusing the company’s future around a core designed for growth.

J&J’s diversification strategy isn’t bad business sense, and it’s a boon for investors craving stability in a volatile market. The stock’s even been one of the best performers on the Dow Jones index this year, as it’s outperformed the market. Yet even on the Dow alone, fellow blue-chip health-care rival Pfizer has topped J&J’s gains, to say nothing of the many other strong pharmaceutical and biotech companies surging this year. J&J’s a great, safe stock for any portfolio to build around, but if you’re looking for the best growth in the industry and are willing to take a chance, there are riskier — and potentially more rewarding — stocks around the sector than Johnson & Johnson (NYSE:JNJ).

The article Why Buying Johnson & Johnson Stock Isn’t for Growth Investors originally appeared on Fool.com.

Fool contributor Dan Carroll has no position in any stocks mentioned. The Motley Fool recommends and owns shares of Johnson & Johnson.

Copyright © 1995 – 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.

blog comments powered by Disqus
Insider Monkey Headlines
Insider Monkey Small Cap Strategy
Insider Monkey Small Cap Strategy

Insider Monkey beat the market by 52 percentage points in 24 months Click to see monthly returns in table format!

Lists

The 10 Laziest Countries in the World

The 10 Most Polluted Countries in the World

The 10 Most Dangerous Cities in America 2014

The Top 10 Gold Producing Countries in the World

The 10 Tallest Buildings in the World

The 10 Richest Stand Up Comedians in the World

The 10 Fattest Countries in the World

The 5 Best Summer Jobs for Teens

The 10 Most Religious Countries in the World Keeping the Faith

The 10 Most Educated Countries in the World

The 10 Most Popular Cell Phones in the World

The 10 Drunkest Countries in the World

The 10 Most Expensive Private Schools in the World

The 10 Smallest Countries in the World

Walking Dead Season 5 Spoilers You’ll Wish You Didn’t Know

The 10 Poorest Countries in the World

The 10 Greenest Countries in the World

The Top 10 Countries with the Highest Population in the World

The 10 Most Visited Countries in the World

The Top 10 Star Wars Characters in the Iconic Series

The 10 Most Expensive Android Phones in the World

5 Reasons Why The Illuminati Is Real and a Threat to Society

The 6 Scariest Halloween Costumes Ever Screamed At

The 4 Biggest Hedge Fund Managers in the World Today

The 15 Most Densely Populated Countries in the World

The 10 Biggest Tea Drinking Countries in the World

Top 6 Ways to Improve Your Checkout Process and Close Sales

The 5 Most Profitable Online Businesses You Can Start Today

The 20 Most Profitable Hospitals in the US

The 5 Most Profitable Home Businesses to Start

The 7 Teams that Will Win the Stanley Cup in 2015

The Top 10 Most Expensive Digital Cameras to Snap Stunning Shots With

The 10 Highest Quality Fast Food Restaurants In America Today

The 8 Best Halloween Decorating Ideas to Spook Up Your House

10 Marvel Women that Should Get a Movie Right Now

The 20 Best Remixes of Popular Songs that Will Make You Forget the Originals

7 Most Expensive Cities in the World

5 Least Expensive Cities in the World

10 Celebrities Who Believe In Scientology

10 High Margin Food Products to Build a Business Around

The 10 Most Expensive Clothing Stores in the United States to Get Decked Out At

The 5 Biggest Kickstarter Scams That Swindled Backers’ Donations

The 10 Most Expensive Boarding Schools In the World

50 Crazy Facts About Japan You Won’t Believe

Top 10 Least Expensive Hybrid Cars to Save the Planet With

The 10 Biggest ‘Gate’ Controversies in History

The 10 States with the Highest Nursing Shortages Leaving Their Hospitals Depleted

The 10 Best Value Investment Blogs that Every Investor Must Read

The 6 Cheapest Boarding Schools in Europe 2015

The 5 Most Expensive Cars To Insure in the World

Subscribe

Enter your email:

Delivered by FeedBurner

X

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 47.6% in its first year! Wondering How?

Download a complete edition of our newsletter for free!